Pasar al contenido principal

Investigación y educación

Enviado por remote_content el

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y Educación

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Impact of SARS-CoV-2 vaccination in healthcare workers in a network of clinics in Latin America. IJID Reg.

Mayo 13, 2022

Leer más

Enfermedades infecciosas

Long-term consequences of the misuse of ivermectin data. Lancet Infect Dis.

Octubre 18, 2021

Leer más

Enfermedades infecciosas

Latin America: Situation and preparedness facing the multi-country human monkeypox outbreak. Lancet Reg Health Am.

Julio 6, 2022

Leer más